| Popis: |
Research into biologically natural substances with antitumor properties, known for their potential to induce fewer side effects and exhibit specificity toward cancerous cells, remains imperative. The pressing demand for novel agents in cancer therapy underscores the intensive investigation of natural products from microorganisms. Penicillium aurantiogriseum, frequently isolated from food and feed, emerges as a promising candidate against pathogenic bacteria and fungi. This species harbors numerous mycotoxins that warrant extensive clinical study due to their potential in cancer treatment. Identifying mycotoxins with anticancer properties produced by P. aurantiogriseum could unveil novel therapeutic targets and enrich the pharmacological landscape. This review provides a comprehensive overview of the utilization of P. aurantiogriseum mycotoxins in cancer research and elucidates therapeutic agents’ advantages and limitations. P. aurantiogriseum produces at least 15 mycotoxins with potent anticancer effects mediated through diverse mechanisms, including enzyme inhibition (e.g., pseurotin), induction of apoptosis (e.g., auranthine, aurantiamides A, aurantiomides A-C, penicillic acid, penitrem, verrucisidinol, acetate verrucosidinol, and chaetoglobosin A), and cell-cycle arrest (e.g., anicequol, aurantiamine, and Taxol). Although certain mycotoxins, such as Taxol, Anacin, and Compactin, are used in commerce, many others remain relatively unexplored. The mycotoxins derived from P. aurantiogriseum hold considerable potential for cancer treatment, offering novel therapeutic avenues and enhancing current treatments through synergistic combinations and advanced delivery systems. |
